Request Demo
Last update 25 Jan 2025
Senl_B1922P
Last update 25 Jan 2025
Overview
Basic Info
Drug Type CAR-T |
Synonyms- |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingEarly Phase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with Senl_B1922PNCT05225831
Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in Patients With R/R B-Cell Acute Lymphoblastic Leukemia
NCT05206071
Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma
NCT04626726
A Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of CAR-T Cell in the Treatment of Adult Relapsed Refractory (R/R) Acute Lymphoblastic Leukemia Bridging Allogeneic Hematopoietic Stem Cell Transplantation
100 Clinical Results associated with Senl_B1922P
Login to view more data
100 Translational Medicine associated with Senl_B1922P
Login to view more data
100 Patents (Medical) associated with Senl_B1922P
Login to view more data
100 Deals associated with Senl_B1922P
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CD19-positive B-cell Precursor acute lymphoblastic leukemia | Phase 1 | CN | 15 Aug 2021 | |
| CD22-positive B-cell Precursor acute lymphoblastic leukemia | Phase 1 | CN | 15 Aug 2021 | |
| Non-Hodgkin's lymphoma refractory | Phase 1 | CN | 01 Apr 2020 | |
| Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | CN | 01 Apr 2020 | |
| refractory acute lymphoid leukemia in relapse | Phase 1 | CN | 01 Apr 2020 | |
| Refractory Indolent Adult Non-Hodgkin Lymphoma | Phase 1 | CN | 01 Apr 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05206071 (EHA2022) Manual  | Not Applicable | 26 | Fludarabine Phosphate+Cyclophosphamide+CAR19/22 (murinized CAR-T cells) | axlmlqihob(cgochtzqhi) = eiknmxfmsz cjtyxfwmpl (ntcpetgudh ) View more | Positive | 12 May 2022 | |
Fludarabine Phosphate+Cyclophosphamide+CAR19/22 (humanized CAR-T cells) | axlmlqihob(cgochtzqhi) = kjnlozqhaf cjtyxfwmpl (ntcpetgudh ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free